Vanguard Personalized Indexing Management LLC Has $7.61 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in IDEXX Laboratories by 6.4%, owning 14,190 shares valued at approximately $7.61 million.
• IDEXX Laboratories reported better-than-expected earnings, with $3.63 earnings per share for the quarter, surpassing the consensus estimate of $3.28.
• Analysts have recently raised their price targets for IDEXX Laboratories, with the average target now at $656.50 and several recommending a "buy" rating.

Vanguard Personalized Indexing Management LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,190 shares of the company's stock after purchasing an additional 848 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in IDEXX Laboratories were worth $7,612,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IDXX. GAMMA Investing LLC raised its position in shares of IDEXX Laboratories by 42.7% during the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company's stock worth $918,000 after purchasing an additional 654 shares during the period. CX Institutional acquired a new stake in shares of IDEXX Laboratories during the first quarter worth $215,000. Simon Quick Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter worth $360,000. Fifth Third Bancorp raised its position in shares of IDEXX Laboratories by 102.2% during the first quarter. Fifth Third Bancorp now owns 6,075 shares of the company's stock worth $2,551,000 after purchasing an additional 3,071 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of IDEXX Laboratories by 13.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock worth $10,731,000 after purchasing an additional 2,931 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $616.15 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The stock's 50-day moving average is $641.49 and its two-hundred day moving average is $543.56. The firm has a market cap of $49.29 billion, a P/E ratio of 51.30, a PEG ratio of 3.99 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm posted $2.44 EPS. The business's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. Piper Sandler reissued a "neutral" rating and set a $700.00 price target (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Morgan Stanley upped their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research report on Friday, August 15th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research report on Monday, August 4th. Finally, BTIG Research upped their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $656.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the transaction, the executive vice president directly owned 7,132 shares of the company's stock, valued at $4,477,041.68. This represents a 54.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at approximately $52,650,885.78. The trade was a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,057 shares of company stock worth $34,293,468. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.